In Vitro Diagnostics Market Report & Analysis 2008-2023
Report Details
This report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics – especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers. Developments in IVD also receive encouraging support from regulators such as the FDA. Visiongain believes that some of the greatest opportunities ever available for diagnostics companies are now there to be seized, with important sales, licensing and partnership developments from the present onwards.
Importantly, this report also covers theranostics, a fusion of drug therapy and diagnostics to optimise efficacy and safety, as well as streamlining drug development. Combining a drug with a diagnostic process or test is also known as companion diagnostics, integrated medicine, pharmacodiagnostics and Dx/Rx partnering. This emerging field is generating strong interest from the healthcare industry and regulatory bodies, with the associated market expanding as the importance of theranostics is recognised, especially in cancer.
In Vitro Diagnostics Market Report & Analysis 2008-2023 examines the market for in vitro diagnostic solutions critically, through comprehensive primary and secondary research. Importantly, IVD is discussed in the context of the wider healthcare market, with a strong emphasis on theranostics and related molecular diagnostics/medicine. In addition to consultation with experts in industry - including full interview transcripts - this research involved a detailed study of relevant documents, industrial reports and current developments. The result is a totally independent in-depth market-based report with detailed analyses and informed opinion.
In particular, this report concentrates on the following essential aspects of the in vitro diagnostics sector:
• Technologies that drive the IVD sector, including those related to theranostics
• Key industrial players in IVD - both established and emerging – including partnerships
• Forecasts of the global IVD market from 2008-2023 - including those of principal market segments, both by disease area and technology
• Forecasts for IVD sales in leading national markets, including China and India
• Forecasts for theranostic applications - including therapeutic areas - from 2008-2023
• Drivers and opportunities in the IVD sector
• Restraints and threats in the IVD sector
• Assessments of relevant business models, technological solutions and associated issues
• Coverage of future trends in IVD and theranostics
• Insight from a comprehensive survey with relevant experts
Why you should buy this report:
• To receive a comprehensive analysis of the prospects for IVD from 2008-2023, including sales by disease area, technology and country
• To discover predicted revenues, growth rates and other key metrics for theranostic solutions from 2008-2023
• To receive the views of experts in the IVD sector regarding current and future trends
• To determine the forces that influence the market for IVD:
• Competition• To find out where the IVD market is heading - both technologically and commercially
• Drivers
• Restraints
• Strengths, weaknesses, opportunities and threats
Visiongain predicts that the markets for IVD and theranostics will exhibit strong growth in revenues from 2008-2023, with significant investments being made by far-sighted companies and healthcare providers. Although still in its early stages of commercial development, molecular diagnostics will increasingly gain acceptance from stakeholders in healthcare. You should be benefiting from this opportunity. You and your company can benefit as a result, gaining early market prominence from high-value products. You cannot afford to ignore current developments in diagnostics, especially as personalised medicine becomes an inevitable reality.
Table of Contents
1 Executive Summary: In Vitro Diagnostics Market 2008-2023
2 Introduction to In-Vitro Diagnostics
2.1 The Continuing Success of the Healthcare Industries is Dependent upon Important Drivers and Restraints
2.1.1 Drivers of Sales in Global Healthcare Markets from 2008-20232.2 What are In Vitro Diagnostic (IVD) Tests?
2.1.2 The Global Healthcare Markets Will Also Face Considerable Restraints Throughout the Foreseeable Future
2.2.1 In Vitro Diagnostics are Medical Assays2.3 Advanced Diagnostics and Personalised Medicine
2.2.2 Diagnosis and Disease Management
2.2.3 Screening of Populations and Risk Factors
2.2.4 How are In Vitro Diagnostic Technologies Regulated by the FDA?
2.2.5 Point-of-Care Testing
2.3.1 Polymerase Chain Reaction (PCR)2.4 The Human Genome Project Has Provided Important Scope for Pharmaceutical and Diagnostics Industries
2.3.2 Need for Better Targeted Medicine to Suit Patient Sub-Populations
2.3.3 The Dawn of Pharmacogenomic Medicine
2.3.4 Completion of the Human Genome Project Has Been a Major Driver of Molecular Diagnostics and Personalised Medicine
2.3.5 Personalised Medicine Will Rely Heavily Upon Theranostics – Cooperation Between Diagnostics and Pharmaceutical Sectors
2.4.1 Human Genome Project Marked Start of Genomic Era2.5 Biomarkers and Theranostics
2.4.2 Harnessing the Genomic Data is a Major Challenge for Science and Healthcare Industries for Many Years to Come
2.5.1 Greater Understanding of Molecular Basis of Disease is Vital2.6 Pharmacogenomics is Increasingly Relevant to Pharmaceutical Development
2.5.2 Biomarkers Are Important for Determining Efficacy and Safety
2.5.3 The Scope of Biomarkers is Vast – The Search Will Intensify in the Years Ahead
2.6.1 Genetic Variation and Response to Therapy2.7 Proteomics Constitutes the "Next Step" After Genomics
2.6.2 Molecular Technologies in Medical Science will Strongly Influence the Pharmaceutical and Molecular Diagnostics Sectors
2.6.3 The Number of Companies and Strategic Alliances is Increasing
2.7.1 Applied Study of Protein Structure and Form is Important to Medical Developments2.8 Personalised Medicine Supported By Theranostics Could Supersede the Existing Blockbuster Model, With Sustainable Revenue Flows Continuing
2.7.2 Elucidating the Relationship Between Genes and Proteins
2.8.1 Personalised Medicine Could Bring Significant Financial Gains for Diagnostics and Pharmaceutical Industries2.9 Companies Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Healthcare Market
2.8.2 Far-Sighted Pharma Companies are Looking Beyond the Present Technological and Commercial Challenges
2.9.1 Product Life Cycle Management (PLM)2.10 Healthcare Stakeholders Can Benefit from Changes to Regulatory Processes
2.9.2 R&D Strategy is Crucial to Success
2.9.3 The Blockbuster “Model” Will Yield to More Segmented Product Development
2.10.1 “Live” Licensing and “In-Life” Testing – The Way Forward?2.11 There is an Expanding Market for In Vitro Diagnostics – Especially Molecular Diagnostics
2.10.2 Limited Approval Leading to Testing for Expanded License
2.10.3 Proposed Framework Could Bring Benefits to Patients While Aiding Drug Developers
2.11.1 Sales Potential for Increasingly Effective Diagnostic Agents is High
2.11.2 Personalised Medicine Will Not Necessarily Mark the End of High Revenues
2.11.3 The Demands of Treating Patient Sub-Populations Now a Prime Commercial Driver in Diagnostics and Pharmaceutical Industries
3 The World In Vitro Diagnostics Market 2013-2023
3.1 Significant Sales Growth Predicted for the Overall Global In Vitro Diagnostics Market from 2007 to 2023
3.1.1 IVD Market Led by Metabolism, Oncology and Infection Market Segments3.2 Global IVD Market Breakdown by Principal Technology
3.1.2 Sales in Oncology Will Be Driven by Need for Early Detection and Determination of Efficacy
3.1.3 Metabolism and Oncology to Increase Market Shares in Overall IVD Market
3.2.1 High Growth for Nucleic Acid Testing3.3 Fast-Growing Technologies in the Nucleic Acid Market Segment
3.2.2 Nucleic Acid Testing is The Fastest Growing Segment of the Global Diagnostics Market
3.2.3 The Developing Role of Molecular Technologies in Clinical Diagnostics
3.2.4 Shift to Molecular Diagnostics with Drive for Personalised Medicine
3.2.5 Limitations to Revenue Growth in the IVD Market
3.2.6 Rise in Market for Diabetes Testing Products
3.2.7 Emerging Technologies Growing in Prominence from 2007 to 2023
3.2.8 Increasingly Important Role of IVD Technologies in Drug Discovery
3.2.9 Genetic Screening Sector has Great Potential as Emerging Technology and Market
3.2.10 Growth Restrained by Pricing Ceilings and Downward Pressures on Healthcare Spending
3.3.1 The Nucleic Acid Segment Contains Some of the Brightest Hopes for the IVD Market3.4 Personalised Medicine Will Become More Prominent in Healthcare With Theranostics Benefiting as a Result
3.3.2 DNA Probes Segment Will Show High Growth from 2007-2023
3.3.3 Nucleic Acid Testing in a Point-of-Care (POC) Setting
3.3.4 Impact of Molecular Medicine Provides a Significant Boost for Molecular Diagnostics
3.3.5 Importance of PCR-Based Technology
3.3.6 Clinical Genetic Testing Still Emergent
3.4.1 Personalised Medicine in its Infancy but Still a Great Hope for Advancement of IVD Sector3.5 The Completion of the Human Genome Project Has Been a Major Driver of Molecular Diagnostics
3.4.2 Theranostics Aids Matching of Patients with Treatments – Helping to Optimise Efficacy and Safety
3.4.3 Greater Use of IVD Tests Could Significantly Reduce Adverse Drug Reactions and Cut Mortality Rates Associated With Drug Treatment
3.5.1 Human Genome Sequencing has Made Matching of Therapy to Genetics and Phenotype a Possibility3.6 Biomarker Technology is Still Emerging – But the Technological and Commercial Potential Remains Very Significant
3.5.2 High Gains for Developers and Marketers of Targeted Therapies and Supporting IVD Tests
3.6.1 Biomarker Use Increasingly Prevalent - but Long Way to Go Still3.7 Protein Chip Technologies Gaining in Importance
3.6.2 Biomarkers Key to Growth of IVD Market from Present Onwards
3.7.1 Protein Chip Technologies in Molecular Diagnostics
3.7.2 What are the Advantages and Limitations of Protein Chip Technologies in Clinical Diagnostics?
3.7.3 Diagnostic Applications of Protein Chip Technologies
3.7.4 Which System Will Lead the Way for Diagnostic Protein Chip Technologies?
3.7.5 Cancer Diagnostics - The Key Field in the Future of Protein Chip Assays
4 Issues Affecting the Molecular Diagnostics Market
4.1 A SWOT Analysis for In Vitro Diagnostics
4.2 Diagnostics Companies Will Continue To Expand Their Presence in the Global Healthcare Industry
4.3 IVD Applications Face Some Commercial Obstacles
4.4 IVD is the Cornerstone of Personalised Medicine
4.4.1 Personalised Drugs are More Likely to Work Safely and Efficaciously4.5 Theranostics will Benefit from FDA’s Guidance on Pharmacogenomic Data Submission
4.4.2 Advanced Screening for Disease Leading to Quicker Diagnoses
4.4.3 Improved Vaccines
4.4.4 Improvements in Drug Discovery and Reduced Cost of Clinical Trials
4.4.5 European Union IVD Directive (98/79/EC)
4.4.6 Medical Errors Cost the US Billions of Dollars
4.5.1 Guidance On Pharmacogenomic Data Submission Will Accelerate The Development of Theranostics4.6 Personalised Medicine is a Strong Driver of the IVD Sector
4.5.2 Distinguishing Patients at a Greater Risk is Vital
4.5.3 In Future Parallel Use of Markers and Drugs Will Become Prevalent
4.6.1 EDMA Cites Theranostics as a Medium-to-Long-Term Driver for Healthcare4.7 Identifying Suitable Biomarkers Remains a Significant Challenge
4.6.2 Personalised Medicine Constitutes a New Chapter In Diagnostics
4.6.3 The Technology for Personalised Medicine Already Exists
4.8 Theranostics Bill Introduced in the US Senate During 2006
4.9 Development of Novel IVD Products May Be Limited by Low Reimbursement – Will Systems Change Advantageously?
4.10 Cancer Diagnostics is an Important Growth Area With Relevance to In Vitro Diagnostics – Especially Theranostics
4.10.1 Cancer is the Main Developmental Area for Greater Use of In Vitro Diagnostics4.11 Collaboration Among Stakeholders is Essential
4.10.2 Drivers of the Market for IVD and Therapeutics in Oncology
4.10.3 The Oncology Market also has some Restraints
4.12 Nucleic Acid Testing Technologies Will Be Decisive in the Development of the Theranostics Market
4.12.1 Nucleic Acid Amplification Techniques4.13 Primary Care and Personal Use of IVD
4.12.2 Techniques are Presently Complicated
4.12.3 Biochips are Promising
4.12.4 Key Players Large and Small Making Gains in Nucleic Acid Testing
4.12.5 Prospects from Now Looking Forward
4.13.1 There is Definitely Scope for Greater Use4.14 Barriers to the Growth of Pharmacogenomics
4.13.2 What Hurdles Must be Overcome for Point-of-Care IVD Technologies to Become Fully Established in Primary Care?
4.13.3 Personal Use of In Vitro Diagnostic Technologies
4.13.4 While Medical Stakeholders Will Benefit from Molecular Diagnostic and Other Applications of Genomics, Concerns Over Privacy Likely to Impede Progress
4.14.1 Pharmacogenomics Still an Emerging Field4.15 Potential Changes to Pharma Regulatory and Developmental Processes Dependent upon IVD
4.14.2 The Complexity of Finding SNP Gene Variations that Affect Drug Responses
4.14.3 Limited Therapeutic Alternatives
4.14.4 Disincentives for Drug Companies to Develop and Produce Multiple Treatments for a Disease
4.14.5 Educating Healthcare Providers
4.15.1 Leading Industry Figures Call for More Flexible Approach to Drug Approval4.16 Adaptive Clinical Trial Design Will Facilitate Interaction with Regulators and Provide Increased Rationalisation of Drug Development
4.15.2 Regulators Acknowledge the Need for Stratification of Treatment Populations
4.15.3 Visiongain Predicts Stratification of Patient Populations Leading to Live-Licensing/In-Life Testing
4.15.4 Stratification of Patients is Key to More Personalised Medicine Sought by Developers and Increasingly Required by Regulators
4.15.5 Traditional Clinical Development has a Significant Disadvantage – Better-Targeted Studies will Take Precedence
4.15.6 Evidence-Based Medicine will Become Increasingly Demanded by Pharma Stakeholders
4.16.1 Adaptive Clinical Trial Design Uses Accumulating Data4.17 Personalised Medicine Driven by Theranostics and Live Licensing/In-Life Testing Will Become Established by 2020
4.16.2 Regulators Should be Involved in the Process
4.16.3 Adaptive Trial Design will Gain Acceptance by Early Next Decade
4.17.1 Drivers for Better-Targeted Medicine4.18 Personalised Medicine Aided by Regulatory Reform will also Face Significant Obstacles
4.17.2 The Prospects for More-Personalised Medicine and Related Diagnostics are Good
4.17.3 FDA Critical Path Initiative is a Progressive Move in the Right Direction
4.18.1 The Complex, Disparate Pharma Industry Will Prove Difficult to Reform, Especially in a Revolutionary Manner4.19 While Personalised Medicine and Better Targeted Clinical Trials are Emerging, Such Developments are Welcomed by the FDA and EMEA
4.18.2 It is Unclear How Extensively New Clinical Testing Models and Supporting Regulation will be Applied
4.19.1 Emerging Developments are Welcomed by Pharma Stakeholders4.20 Pricing of Personalised Medicine
4.19.2 Cancer Drug Development Leads the Way in its Merging of Drug Development and Treatment of the Disease
4.19.3 FDA's Critical Path Initiative and Personalised Medicine
4.20.1 Personalised Medicine will Lead to Changes in Pricing and Reimbursement4.21 The Outlook for In Vitro Diagnostics is Exciting
4.20.2 Onus is on Companies to Prove Benefits of their Drugs Including Comparative Cost-Benefits
4.20.3 Biomarkers Can Create Value
4.20.4 The Developments are Complex and Systemic, Posing both Opportunities and Challenges for Healthcare Stakeholders
5 Leading Players and Developments in the IVD Sector
5.1 Profiles of Some Important In Vitro Diagnostics Companies
5.1.1 Roche Diagnostics Division5.2 Spotlight on Emerging Companies with High Promise in IVD Technologies
5.1.2 Abbott Diagnostics
5.1.3 Gen-Probe Inc.
5.1.4 LifeScan Inc.
5.1.5 Axis-Shield
5.1.6 Clinical Data Inc and PGxHealth
5.1.7 Visible Genetics
5.1.8 NGI
5.2.1 Proteome Sciences – Harnessing Proteomics5.3 Landmark Developments in Theranostics
5.2.2 Investigen – Novel DNA Testing Applications
5.2.3 DxS Ltd – Facilitating Personalised Medicine
5.2.4 HBV Theranostica – IVD Solutions for Hepatitis B
5.2.5 Enigma Diagnostics - Exciting Developments in Rapid Detection
5.2.6 Itsi-Biosciences – Technology for Proteomics and Biomarker Discovery
5.2.7 Amorfix Life Sciences and Biogen Idec – an Important Partnership
5.2.8 MLT Research Ltd – Technologies Important to IVD
5.2.9 Innogenetics – Ambitious Programme in Theranostics
5.2.10 A&G Pharmaceutical – Solutions for Cancer Theranostics
5.3.1 Genentech’s Herceptin and Novartis’ Gleevec are Probably the Best Known5.4 Protein Chip Technologies for Clinical Diagnosis
5.3.2 PharmaNetics’ Thrombolytic Assessment System – Pioneers in the Field
5.3.3 Genentech and DakoCytomation: Herceptin and HercepTest
5.3.4 ImClone Systems and DakoCytomation: Erbitux and EGFR pharmDx Test
5.3.5 Abbott Laboratories’ PathVysion HER-2 DNA Probe Kit
5.3.6 Bayer Diagnostics and Oncogene Science
5.3.7 Novartis and Ventana Medical Systems: Gleevec and VentanaDx c-Kit
5.4.1 ProteinChip by Ciphergen
5.4.2 Trinectin Proteome Chip by Phylos
5.4.3 Triage by Biosite
5.4.4 Tissue Microarray Technology
5.4.5 Molecular Diagnostics and Antigen-Antibody Interactions
6 In Vitro Diagnostic Sales in the Leading Developed and Developing Nations, 2007-2023
6.1 Expansion of the World Market Boosted by Increasing Sales in the Developing Healthcare Markets
6.1.1 High Sales in Developed Markets but India and China Catching Up
6.1.2 US to Lead World Market but Leading Developing Markets Exhibiting Highest Growth
6.2 Market Shares of Leading Nations for IVD Sales
6.2.1 US to Lose Market Share to India and China in Particular
6.3 There Will be High Sales Growth in Both Developed and Developing Markets for Diagnostics in the Years Ahead
6.3.1 US is Largest IVD Market
6.3.2 Potential for Sales Growth in Developing Countries is Significant
6.3.3 Improving Access to Modern Healthcare is a Principal Driver of Growth in Developing Nations
6.4 China and India are the Most Exciting New Prospects for the IVD Industry
6.4.1 China and India Both Have the Potential to be Leading Economic Nations
6.4.2 Strategies for Market Entry and Consolidation are Vital for Diagnostics Companies
6.5 WTO Agreements Affect Developments in Emerging Markets
6.5.1 The Principal Diagnostics Markets Remain the Leading Developed Nations But Developing Nations Are Increasingly Important
6.5.2 Expansion into Developing National Markets Will Help to Bring the IVD Industry to a New Level of Commercial Success
7 Theranostics Market Analysis, 2007-2023
7.1 Theranostic Products Will Constitute a Major Driver of the Global IVD Market
7.1.1 IVD Theranostics Market to Expand to Multi-Billion Dollar Sales by 20137.2 Market Share Gains in Prominent Market Segments
7.1.2 Drive for Personalised Medicine to Boost Theranostic Revenues
7.1.3 Fastest Growth in Cardiovascular & Respiratory and Oncology Segments
7.2.1 Cardiovascular & Respiratory and Oncology Segments to Gain Market Share from Present Onwards7.3 Theranostics is Essentially a Fusion of Drug Therapy and Diagnostics
7.2.2 CNS Segment to Lose Market Share from 2007 Onwards
7.3.1 Diagnosis and Treatment Brought Closer Together7.4 Industry Has Been Relatively Slow to Adopt Theranostics - But That Situation Is Changing
7.3.2 Reduction of ADRs
7.3.3 Narrowing of Gap Between Diagnostics and Pharmaceuticals
7.3.4 Recent Advances in Biomedical Sciences Have Made Theranostics Possible
7.3.5 Genentech’s Herceptin is a Prominent Example of the Theranostics Approach
7.3.6 Recent FDA Publication Places Increasing Importance on Theranostics
7.4.1 Trends in Healthcare are Increasingly Favouring Theranostics7.5 Theranostics Will Take Off In a Few Important Therapy Areas First
7.4.2 Will The Success of Theranostics Lead To a Shift in Spending From Drugs to Diagnostics?
7.5.1 There are Exciting Possibilities for Theranostics7.6 The Improvement in Clinical Performance from Theranostics Will Make It Easier To Justify Costs to Payers
7.5.2 Cancer Diagnostic Technologies Constitute a Particularly Important Application
7.6.1 Theranostics Can be a Win-Win for Diagnostics and Pharma Industries7.7 Personalised Medicine Supported By Theranostics Could Supersede the Existing Blockbuster Model, With Sustainable Revenue Flows Continuing
7.6.2 A Theranostic Combination Can Provide an Important Competitive Advantage
7.7.1 Market is Expanding with Technology Flourishing
7.7.2 The Market for Theranostic Products Is Creating Significant Opportunities for Many Companies in the Pharmaceutical, Diagnostics and Biotechnological Sectors
7.7.3 Rising Health Insurance Coverage Will Benefit the Market
7.7.4 Inter-Industry Links Will Continue to Drive the Theranostics Market
7.7.5 Key Factors Required for Success in the Theranostics Market
8 Interviews with Industry Experts: In Vitro Diagnostics - Current and Future Trends
8.1 Interview 1: Director of a Diagnostics Company
8.1.1 Most Promising Therapeutic areas for IVD8.2 Interview 2: CEO of a Diagnostics Company
8.1.2 Un-Met Medical Needs in IVD
8.1.3 Greatest Obstacles to Market Growth
8.1.4 Prospects for IVD Market Growth in the Developing Nations
8.1.5 Prospects for Theranostics
8.2.1 Most Promising Therapeutic areas for IVD8.3 Interview 3: Director of a Diagnostics Company
8.2.2 Un-Met Medical Needs in IVD
8.2.3 Greatest Obstacles to Market Growth
8.2.4 Prospects for IVD Market Growth in the Developing Nations
8.2.5 Prospects for Theranostics
8.3.1 Most Promising Therapeutic areas for IVD8.4 Interview 4: Business Development Director of a Diagnostics Company
8.3.2 Un-Met Medical Needs in IVD
8.3.3 Greatest Obstacles to Market Growth
8.3.4 Prospects for IVD Market Growth in the Developing Nations
8.3.5 Prospects for Theranostics
8.4.1 Most Promising Therapeutic areas for IVD8.5 Responses from a KOL Survey on Theranostics
8.4.2 Un-Met Medical Needs in IVD
8.4.3 Greatest Obstacles to Market Growth
8.4.4 Prospects for IVD Market Growth in the Developing Nations
8.4.5 Prospects for Theranostics
8.5.1 How Influential Will Theranostics Be In Coming Years?
8.5.2 Comment on Responses
8.5.3 Are Pharmaceutical and Diagnostic Companies Ready for Closer Links?
8.5.4 Comment on Responses
8.5.5 Will Theranostics Contribute Significantly to Clinical Trials?
8.5.6 Visiongain Comment on Responses
8.5.7 In What Areas Will Theranostics Be Most Prominent?
8.5.8 Visiongain Comment on Responses
9 Conclusions
9.1 In Vitro Diagnostics are Vital to Clinical Decision Making
9.2 Significant Growth of In Vitro Diagnostics Market from 2007 to 2023
9.3 Personalised Medicine Will Rely Heavily Upon Theranostics – Cooperation Between Diagnostics and Pharmaceutical Sectors
9.4 Expansion of the World Market Boosted by Increasing Sales in the Developing Healthcare Markets
9.5 Expansion into Developing National Markets and Lifestyle Diseases Will Drive Market
Appendices
Appendix A: Glossary
Appendix B: Notes on FDA Classification and Regulation of IVD Applications
Appendix C: EC Classification of In Vitro Diagnostic Medical Devices
Appendix D: In Vitro Diagnostics: Prominent Companies
Appendix E: About visiongain
Appendix F: Visiongain report evaluation form
List of Tables
Table 3.1 Sales ($bn) for the World In Vitro Diagnostic Market by Disease Area, 2007-2013
Table 3.2 Sales ($bn) for the World In Vitro Diagnostic Market by Disease Area, 2014-2020
Table 3.3 CAGR (%) for the World In Vitro Diagnostic Market by Disease Area, 2007-2020
Table 3.4 World IVD Market by Disease Area: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 3.5 Market Share (%) for the World In Vitro Diagnostic Market by Disease Area, 2007, 2014, 2018 and 2023
Table 3.6 Sales ($bn) for the World In Vitro Diagnostic Market by Principal Technology, 2007-2013
Table 3.7 Sales ($bn) for the World In Vitro Diagnostic Market by Principal Technology, 2014-2020
Table 3.8 CAGR (%) for the World In Vitro Diagnostic Market by Principal Technology, 2007-2020
Table 3.9 World In Vitro Diagnostic Market by Principal Technology: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 3.10 Market Share (%) for the World In Vitro Diagnostic Market by Principal Technology, 2007, 2014, 2018 and 2023
Table 3.11 Sales ($bn) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007-2013
Table 3.12 Sales ($bn) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2014-2020
Table 3.13 CAGR (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007-2020
Table 3.14 Nucleic Acids Segment of the World IVD Market by Sub Technology: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 3.15 Market Share (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007, 2014, 2018 and 2023
Table 4.1 A SWOT Chart for In Vitro Diagnostic Applications, 2008-2023
Table 4.2 Greater Use of Disease Knowledge and Biomarkers Will Benefit Pharmaceutical Development
Table 6.1 Sales ($bn) for the World In Vitro Diagnostic Market by Leading Nation, 2007-2013
Table 6.2 Sales ($bn) for the World In Vitro Diagnostic Market by Leading Nation, 2014-2020
Table 6.3 CAGR (%) for the World In Vitro Diagnostic Market by Leading Nation, 2007-2020
Table 6.4 World In Vitro Diagnostic Market by Leading Nation: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 6.5 Market Share (%) for the World In Vitro Diagnostic Market by Leading Nation, 2007, 2014, 2018 and 2023
Table 7.1 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2007-2013
Table 7.2 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2014-2020
Table 7.3 CAGR (%) for the World IVD Theranostics Market by Disease Area, 2007-2020
Table 7.4 World IVD Theranostics Market by Disease Area: Long Range Sales Forecasts ($bn) with CAGR (%), 2007-2023
Table 7.5 World IVD Theranostics Market Sales Compared With Overall IVD Market ($bn), Market Share (%) and CAGR (%), 2007-2023
Table 7.6 Market Share (%) for the World IVD Theranostics Market by Disease Area, 2007, 2014, 2018 and 2023
List of Figures
Figure 1.1 Total Sales ($bn) for the World In Vitro Diagnostic Market, 2007-2020
Figure 2.1 The Drug Development Process is Long, Complex and Costly
Figure 3.1 Sales ($bn) for the World In Vitro Diagnostic Market by Disease Area, 2007-2013
Figure 3.2 Total Sales ($bn) for the World In Vitro Diagnostic Market, 2007-2013
Figure 3.3 Sales ($bn) for the World In Vitro Diagnostic Market by Disease Area, 2014-2020
Figure 3.4 Total Sales ($bn) for the World In Vitro Diagnostic Market, 2014-2020
Figure 3.5 Market Share (%) for the World In Vitro Diagnostic Market by Disease Area, 2007
Figure 3.6 Market Share (%) for the World In Vitro Diagnostic Market by Disease Area, 2014
Figure 3.7 Market Share (%) for the World In Vitro Diagnostic Market by Disease Area, 2018
Figure 3.8 Market Share (%) for the World In Vitro Diagnostic Market by Disease Area, 2023
Figure 3.9 Sales ($bn) for the World In Vitro Diagnostic Market by Principal Technology, 2007-2013
Figure 3.10 Sales ($bn) for the World In Vitro Diagnostic Market by Principal Technology, 2014-2020
Figure 3.11 Market Share (%) for the World In Vitro Diagnostic Market by Principal Technology, 2007
Figure 3.12 Market Share (%) for the World In Vitro Diagnostic Market by Principal Technology, 2014
Figure 3.13 Market Share (%) for the World In Vitro Diagnostic Market by Principal Technology, 2018
Figure 3.14 Market Share (%) for the World In Vitro Diagnostic Market by Principal Technology, 2023
Figure 3.15 Sales ($bn) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007-2013
Figure 3.16 Total Sales ($bn) for the Nucleic Acids Segment of the World IVD Market, 2007-2013
Figure 3.17 Sales ($bn) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2014-2020
Figure 3.18 Sales ($bn) for the Nucleic Acids Segment of the World IVD Market, 2014-2020
Figure 3.19 Market Share (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2007
Figure 3.20 Market Share (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2014
Figure 3.21 Market Share (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2018
Figure 3.22 Market Share (%) for the Nucleic Acids Segment of the World IVD Market by Sub Technology, 2023
Figure 4.1 How Pharmaceutical Development Will Evolve into a More Progressive System
Figure 4.2 The Dynamic Integrated Regulatory System of the Future
Figure 4.3 Systemic Changes to Pharmaceutical Regulation Involve all Healthcare Stakeholders
Figure 6.1 Sales ($bn) for the World In Vitro Diagnostic Market by Leading Nation, 2007-2020
Figure 6.2 Sales ($bn) for the World In Vitro Diagnostic Market by Leading Nation, 2007-2020 (Continued)
Figure 6.3 Market Share (%) for the World In Vitro Diagnostic Market by Leading Nation, 2007
Figure 6.4 Market Share (%) for the World In Vitro Diagnostic Market by Leading Nation, 2014
Figure 6.5 Market Share (%) for the World In Vitro Diagnostic Market by Leading Nation, 2018
Figure 6.6 Market Share (%) for the World In Vitro Diagnostic Market by Leading Nation, 2023
Figure 7.1 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2007-2013
Figure 7.2 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2007-2013 (Continued)
Figure 7.3 Total Sales ($bn) for the World IVD Theranostics Market, 2007-2013
Figure 7.4 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2014-2020
Figure 7.5 Sales ($bn) for the World IVD Theranostics Market by Disease Area, 2014-2020 (Continued)
Figure 7.6 Total Sales ($bn) for the World IVD Theranostics Market, 2014-2020
Figure 7.7 World IVD Theranostics Market Sales Compared With Overall IVD Market ($bn), 2007, 2018 and 2023
Figure 7.8 Total IVD Theranostics Share (%) of World IVD Market, 2007, 2018 and 2023
Figure 7.9 Market Share (%) for the World IVD Theranostics Market by Disease Area, 2007
Figure 7.10 Market Share (%) for the World IVD Theranostics Market by Disease Area, 2014
Figure 7.11 Market Share (%) for the World IVD Theranostics Market by Disease Area, 2018
Figure 7.12 Market Share (%) for the World IVD Theranostics Market by Disease Area, 2023
Other users found this report page using the following search terms: IVD In Vitro Diagnostics theranostics molecular diagnositcs market vitro diagnostics diagnostic india 2008 companies ivd company share
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.